Schizophrenia

Schizophrenia Symptom Improvements and Adverse Effects

Schizophrenia Symptom Improvements and Adverse Effects

By

Participants in the risperidone group were generally more likely to achieve a significant clinical improvement in their mental state.

Schizophrenia Treatment Outcomes Favor Cariprazine Over Risperidone

Schizophrenia Treatment Outcomes Favor Cariprazine Over Risperidone

By

Cariprazine treatment led to greater improvement in the negative symptoms of schizophrenia than risperidone.

FDA Approves New Schizophrenia Treatment for Adolescents

FDA Approves New Schizophrenia Treatment for Adolescents

By

The FDA has approved a new treatment for adolescents between the ages of 13 and 17 years who are diagnosed with schizophrenia.

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

By

Researchers profiled which young people may do well after first-episode psychosis without medication.

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

By

These study results indicate that early intervention with low doses of metformin in patients with few metabolic abnormalities may be beneficial.

Facial Affect Recognition Training Improves Social Outcomes in Psychosis

Facial Affect Recognition Training Improves Social Outcomes in Psychosis

By

Inability to interpret facial expressions may exacerbate psychotic symptoms, either indirectly via social defeat or directly by creating confusing interpersonal experiences.

Slightly Higher HIV Screening in Patients With Severe Mental Illness

Slightly Higher HIV Screening in Patients With Severe Mental Illness

This study included Medicaid patients taking medications to treat bipolar disorder, schizophrenia, or major depression with psychosis.

Predictors of Favorable Outcomes in First-Episode Psychosis Without Medication

Predictors of Favorable Outcomes in First-Episode Psychosis Without Medication

By

Young patients with first-episode psychosis may be able to achieve recovery.

Underlying Mechanism of Auditory Impairment in Schizophrenia Reveals Potential Therapeutic Path

Underlying Mechanism of Auditory Impairment in Schizophrenia Reveals Potential Therapeutic Path

By

Benefits of NMDA receptor agonists in patients with schizophrenia include improvements with memory and reading.

No Difference Between Omega-3 & Placebo in Patients at Ultrahigh Risk for Psychosis

No Difference Between Omega-3 & Placebo in Patients at Ultrahigh Risk for Psychosis

By

PUFA supplementation offers little additional aid to psychosis when good psychosocial care is already sought.

Gene Expression Patterns in Polygenic Schizophrenia Risk

Gene Expression Patterns in Polygenic Schizophrenia Risk

By

Data indicate that 693 genes are differentially expressed between individuals diagnosed with schizophrenia and typical, healthy controls.

Ambiguity Aversion is Attenuated in Schizophrenia

Ambiguity Aversion is Attenuated in Schizophrenia

By

Researchers conducted an fMRI study of decision-making under conditions of risk and ambiguity in patients diagnosed with schizophrenia.

Low Levels of Vitamin D in Patients With Bipolar Disorder

Low Levels of Vitamin D in Patients With Bipolar Disorder

By

Approximately 2.5% of people worldwide are estimated to have bipolar spectrum disorders, which are a significant cause of neuropsychiatric disability.

Haloperidol in the Emergency Department Setting

Haloperidol in the Emergency Department Setting

By

Dr. Scott Zeller suggests it is time to move away from emergency intramuscular haloperidol.

Effort Allocation Influences Upon Cognition in Schizophrenia

Effort Allocation Influences Upon Cognition in Schizophrenia

By

Researchers studied social cognition and social problem solving in patients with schizophrenia by employing a validated test designed to assess emotion recognition abilities.

Delusions in Schizophrenia Associated With Myelin Abnormalities, Neuroinflammation

Delusions in Schizophrenia Associated With Myelin Abnormalities, Neuroinflammation

By

Study provides further evidence for the effects of white matter fiber abnormalities and neuroinflammation on positive symptoms in patients with schizophrenia.

Gene Sets Altered Across Brain Regions in Schizophrenia, Bipolar Disorder & MDD

Gene Sets Altered Across Brain Regions in Schizophrenia, Bipolar Disorder & MDD

By

Until now, the majority of postmortem research that has examined functionally related gene sets has been limited to a single disorder or region of the brain.

Bipolar and Schizophrenia Disorders Accurately Predicted With WERCAP Sections

Bipolar and Schizophrenia Disorders Accurately Predicted With WERCAP Sections

By

By using the Washington Early Recognition Center Affectivity and Psychosis (WERCAP) questionnaire, investigators accurately predicted bipolar disorder or schizophrenia in more than 85% of patients.

White Matter Abnormalities and Clinical Symptom Severity in Schizophrenia

White Matter Abnormalities and Clinical Symptom Severity in Schizophrenia

By

New findings provide an insight about the association between white matter microstructure and the severity of schizophrenia clinical symptoms.

Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar Disorder

Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar Disorder

By

The authors explored whether valproate (VPA) treatment effects vary by catechol-O-methyltransferase (COMT) genotype.

Neuroimaging of Schizophrenia: The Importance of Illness Severity and Duration

Neuroimaging of Schizophrenia: The Importance of Illness Severity and Duration

By

Researchers used voxel-based morphometry, which allows examination on a voxel-wise basis across the whole brain, to assess whether structural abnormalities in schizophrenia are static or progressive.

mPFC Abnormalities Associated With Social Cognition Deficits in Schizophrenia

mPFC Abnormalities Associated With Social Cognition Deficits in Schizophrenia

By

Poor psychosocial functioning among individuals diagnosed with schizophrenia is associated with deficits in social cognition.

Neuroinflammation in Schizophrenia: New PET Brain Imaging Studies

Neuroinflammation in Schizophrenia: New PET Brain Imaging Studies

By

TSPO expression is frequently used as a biomarker for brain inflammation during PET imaging.

Clinical, But Not Subclinical, Psychosis Linked with Less Physical Activity

Clinical, But Not Subclinical, Psychosis Linked with Less Physical Activity

By

Low physical activity was defined as less than 150 minutes of moderate-to-vigorous exercise per week.

A Potential Biomarker for the Onset of Psychosis in High-risk Individuals

A Potential Biomarker for the Onset of Psychosis in High-risk Individuals

By

Researchers used the auditory mismatch negativity (MMN) paradigm to evaluate its potential as a neurophysiological biomarker for psychosis.

Poorly Organized Fiber Tracts in Patients With Schizophrenia

Poorly Organized Fiber Tracts in Patients With Schizophrenia

By

Investigators examined the white matter tracts in patients diagnosed with the schizophrenia with predominantly negative symptoms.

Cannabinoid Receptor System Dysregulation in Schizophrenia

Cannabinoid Receptor System Dysregulation in Schizophrenia

By

Researchers explored the role of the dysregulated cannabinoid receptor system in patients diagnosed with schizophrenia.

How Reliable Are Patient-reported Outcomes in Schizophrenia?

How Reliable Are Patient-reported Outcomes in Schizophrenia?

By

The primary outcome in this study was reliability of patient-ratings on subjective well-being.

Personalized Treatment With Second vs. First Generation Antipsychotics

Personalized Treatment With Second vs. First Generation Antipsychotics

By

The primary outcome in this study was the change in total quality-of-life scores from baseline to week 24 after patients were randomly assigned to a treatment group.

Cognition and White Matter Alterations in Schizophrenia, Bipolar Disorder

Cognition and White Matter Alterations in Schizophrenia, Bipolar Disorder

By

Direct comparison of white matter tracts between individuals with schizophrenia or bipolar disorder has not been performed to date.

Sign Up for Free e-newsletters